Bayer Cropscience rallies as it posts exponential margin growth in Q4!

Trending Company

by 5paisa Research Team Last Updated: 2022-05-25T16:20:01+05:30

At today’s intraday high of Rs 5078.55, shares of Bayer Cropscience surged 7.2% from the previous close. The rally was triggered by robust Q4 and FY22 results declared by the company.  

For Q4FY22, its net revenue from operations increased by 31.29% YoY and came in at Rs 963.3 crore as against Rs 733.7 crore a year ago, however it declined by 2.71% on a sequential basis. New product launches and overall strong crop sentiments were key drivers for sales growth in Q4. EBITDA grew exponentially by 142.68% YoY to Rs 200.7 crore in Q4FY22 from Rs 82.7 crore a year ago. PAT stood at Rs 152.7 crore compared to Rs 61.9 crore a year ago growing 1.47X on YoY.  

In Q4FY22, EBIDTA margins improved significantly by 956 bps YoY from 11.27% to 20.83%. The PAT margins stood at 15.85% in Q4FY22 with a growth of 741 bps YoY. Bayer was successful in delivering market upbeat numbers in Q4 despite headwinds from supply chain disruptions and inflationary pressure on input costs which was partially offset by price increases.  

The company reported Revenue from Operations of Rs 4734.4 crore in FY 2021-22, up from Rs 4261.3 crore the previous year, representing an increase of 11% in overall revenue. Profit after Exceptional Items & Tax increased by 31% from Rs 493.1 crore to Rs 645.3 million. During the year, the company had an exceptional income of Rs 58.5 crore arising from the sale of part of the seed distribution business viz. mustard, cotton, millet and sorghum seeds.  

Bayer is among the market leaders in the crop science segment in India with a 14-15% market share. The company’s strengths lie in its digital innovation, expansion of farmer reach through new business models and farmer engagements.  

At market close , Bayer was at Rs 4933 with a gain of 4.13 per cent or Rs 195.45 per share. 


Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Disclaimer

Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

Open Free Demat Account

& get benefits worth 2100*

 
Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number